2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 207.920 | 259.938 | 284.342 | 331.260 | 344.973 | 321.038 | 438.351 | 386.975 | 392.286 | 415.466 |
Total Income - EUR | 212.700 | 275.784 | 290.930 | 337.230 | 350.594 | 323.979 | 441.064 | 387.672 | 394.225 | 416.080 |
Total Expenses - EUR | 192.720 | 256.686 | 267.395 | 298.760 | 309.505 | 291.778 | 386.516 | 344.356 | 356.829 | 379.085 |
Gross Profit/Loss - EUR | 19.979 | 19.098 | 23.535 | 38.470 | 41.088 | 32.201 | 54.548 | 43.316 | 37.397 | 36.995 |
Net Profit/Loss - EUR | 17.138 | 16.326 | 20.171 | 34.902 | 37.582 | 29.134 | 51.082 | 40.490 | 33.527 | 33.325 |
Employees | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
Check the financial reports for the company - Alipharm S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 12.489 | 11.444 | 5.157 | 4.850 | 4.412 | 2.096 | 5.269 | 3.460 | 31.344 | 25.470 |
Current Assets | 244.098 | 256.712 | 245.843 | 256.826 | 260.552 | 261.465 | 280.116 | 277.935 | 124.086 | 146.307 |
Inventories | 136.709 | 233.180 | 229.774 | 228.735 | 224.355 | 236.300 | 238.239 | 230.197 | 73.018 | 84.360 |
Receivables | 10.195 | 11.364 | 7.339 | 22.653 | 26.037 | 23.682 | 35.707 | 36.761 | 49.518 | 45.144 |
Cash | 97.194 | 12.168 | 8.730 | 5.437 | 10.161 | 1.482 | 6.170 | 10.977 | 1.549 | 16.804 |
Shareholders Funds | 185.565 | 199.221 | 20.505 | 55.060 | 91.428 | 115.675 | 164.563 | 201.404 | 33.941 | 67.163 |
Social Capital | 112 | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 |
Debts | 71.022 | 68.935 | 230.495 | 206.616 | 173.536 | 147.966 | 120.822 | 80.000 | 118.650 | 102.390 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.839 | 2.224 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Alipharm S.r.l.